NCT04923139View on ClinicalTrials.gov

A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims Database

CompletedOBSERVATIONAL
Enrollment

2,627

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Treatment of Venous Thromboembolism
Interventions
DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Dosage at the discretion of the treating physician

Trial Locations (2)

Unknown

Japan databases, Japan Databases

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY